At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 641 enrolled
Drug / intervention
Nebivolol +1 moredrug
Likely dose
Nebivolol 20 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety of Nebivolol in Younger Patients (18 - 54 Years) Who Have Stage 1 or 2 Essential Hypertension
In Brief
A Phase 4 clinical trial evaluating Nebivolol and Placebo for Hypertension. Completed, enrolled 641 participants across 75 sites.
Detailed Summary
The purpose of this study is to assess the efficacy, safety, and tolerability of 8 weeks of therapy with nebivolol in comparison to placebo in younger patients 18 - 54 years of age with stage 1 or stage 2 essential hypertension.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypertension
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartAug 2011
First PostedAug 2011
Primary CompletionMar 2012
Study CompletionApr 2012
TodayJul 2026
First PostedAug 12, 2011
Enrollment StartAug 1, 2011
Primary CompletionMar 1, 2012
Study CompletionApr 1, 2012
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 14.9 years ago
Interventions
Nebivololdrug
Nebivolol (non-trade 5, 10 or 20 mg tablet), oral administration
Placebodrug
Dose-match placebo